Denatured G-protein coupled receptors as immunogens to generate highly specific antibodies

PLoS One. 2012;7(9):e46348. doi: 10.1371/journal.pone.0046348. Epub 2012 Sep 27.

Abstract

G-protein coupled receptors (GPCRs) play a major role in a number of physiological and pathological processes. Thus, GPCRs have become the most frequent targets for development of new therapeutic drugs. In this context, the availability of highly specific antibodies may be decisive to obtain reliable findings on localization, function and medical relevance of GPCRs. However, the rapid and easy generation of highly selective anti-GPCR antibodies is still a challenge. Herein, we report that highly specific antibodies suitable for detection of GPCRs in native and unfolded forms can be elicited by immunizing animals against purified full length denatured recombinant GPCRs. Contrasting with the currently admitted postulate, our study shows that an active and well-folded GPCR is not required for the production of specific anti-GPCR antibodies. This new immunizing strategy validated with three different human GPCR (μ-opioid, κ-opioid, neuropeptide FF2 receptors) might be generalized to other members of the GPCR family.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antibodies / immunology*
  • Antibodies / isolation & purification
  • Humans
  • Immunization
  • Immunoglobulin G / biosynthesis*
  • Immunoglobulin G / immunology
  • Immunoglobulin G / isolation & purification
  • Mice
  • Mice, Inbred BALB C
  • Molecular Sequence Data
  • Pichia / genetics
  • Protein Denaturation
  • Protein Folding
  • Receptors, Neuropeptide / administration & dosage
  • Receptors, Neuropeptide / genetics
  • Receptors, Neuropeptide / immunology*
  • Receptors, Opioid, kappa / administration & dosage
  • Receptors, Opioid, kappa / genetics
  • Receptors, Opioid, kappa / immunology*
  • Receptors, Opioid, mu / administration & dosage
  • Receptors, Opioid, mu / genetics
  • Receptors, Opioid, mu / immunology*
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / genetics
  • Recombinant Proteins / immunology

Substances

  • Antibodies
  • Immunoglobulin G
  • Receptors, Neuropeptide
  • Receptors, Opioid, kappa
  • Receptors, Opioid, mu
  • Recombinant Proteins

Grants and funding

This work was supported by the Centre National de la Recherche Scientifique (CNRS), the Institut National de la Santé et de la Recherche Médicale (INSERM), and the Université Paul Sabatier, Toulouse III. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.